People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Semaglutide (known by its brand name Ozempic) has gained widespread attention for its weight-loss benefits, but is officially ...

Although it is best known for treating type 2 diabetes, semaglutide — known by its brandname Ozempic — may also be effective ...